Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levocetirizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | TEK | Q02763 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | DRD4 | P21917 | 1/20 | 0.74 |
| ▸ | HTR7 | P34969 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cetirizine SCHEMBL13724610 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Levocetirizine SCHEMBL5935097 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL2455487 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL5526985 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL4176 | 1.00 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL6474316 | 0.99 | DRD3 (0.98) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL2430457 | 0.99 | DRD3 (0.98) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL41107 | 0.99 | HRH1 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Levocetirizine SCHEMBL2255374 | 0.99 | HRH1 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL5520719 | 0.99 | HRH1 (1.00) | DRD3HRH1USP2HRH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10224 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106952-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | CDG CARE (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260124196-A1 | LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF SEPSIS AND SYMPTOMS THEREOF | IRR INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260115184-A1 | DOSING REGIMEN FOR INJECTABLE CETIRIZINE | JDP THERAPEUTICS LLC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | claimed |
| WO-2003042174-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2003-05-22 | — | — | WO | claimed |
| CN-1418630-A | Solution agent of antiallergi medicine contg. levocetirizine | HUABANG PHARMACEUTICAL CO LTD (CN) | 2003-05-21 | — | — | CN | claimed |
| US-20030082212-A1 | Allergy treatment method using a rapid immunotherapy protocol | SMITS WILLIAM (US) | 2003-05-01 | — | — | US | claimed |
| US-20030055077-A1 | Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists | JONES THOMAS R (CA) | 2003-03-20 | — | — | US | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
| EP-1274457-A2 | METHOD AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC CONDITIONS USING PGD2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2003-01-15 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| US-20010051624-A1 | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists | JONES THOMAS R (CA) | 2001-12-13 | — | — | US | claimed |
| US-6319927-B1 | SIDE EFFECT REDUCTION | SCHERING CORPORATION | 2001-11-20 | — | — | US | claimed |
| WO-2001078697-A2 | METHOD AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC CONDITIONS USING PGD2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2001-10-25 | — | — | WO | claimed |